A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,387,267 shares of BPMC stock, worth $486 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
5,387,267
Previous 5,873,392 8.28%
Holding current value
$486 Million
Previous $633 Million 21.28%
% of portfolio
0.06%
Previous 0.08%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$84.1 - $120.5 $40.9 Million - $58.6 Million
-486,125 Reduced 8.28%
5,387,267 $498 Million
Q2 2024

Aug 14, 2024

SELL
$85.18 - $108.78 $32.1 Million - $41.1 Million
-377,431 Reduced 6.04%
5,873,392 $633 Million
Q1 2024

May 15, 2024

BUY
$73.17 - $99.79 $60.1 Million - $82 Million
821,868 Added 15.14%
6,250,823 $593 Million
Q4 2023

Feb 14, 2024

SELL
$43.96 - $92.84 $2.97 Million - $6.28 Million
-67,622 Reduced 1.23%
5,428,955 $501 Million
Q3 2023

Nov 14, 2023

SELL
$46.9 - $66.0 $5.95 Million - $8.37 Million
-126,799 Reduced 2.25%
5,496,577 $276 Million
Q2 2023

Aug 14, 2023

BUY
$42.2 - $66.37 $28.5 Million - $44.8 Million
674,942 Added 13.64%
5,623,376 $355 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $24.6 Million - $32.5 Million
649,144 Added 15.1%
4,948,434 $223 Million
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $11 Million - $17.8 Million
267,479 Added 6.63%
4,299,290 $188 Million
Q3 2022

Nov 14, 2022

SELL
$49.93 - $77.7 $79.9 Million - $124 Million
-1,599,876 Reduced 28.41%
4,031,811 $266 Million
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $31.6 Million - $49 Million
698,562 Added 14.16%
5,631,687 $284 Million
Q1 2022

May 16, 2022

BUY
$54.1 - $110.08 $20.7 Million - $42.1 Million
382,586 Added 8.41%
4,933,125 $315 Million
Q4 2021

Feb 14, 2022

BUY
$94.25 - $115.99 $16.8 Million - $20.7 Million
178,711 Added 4.09%
4,550,539 $487 Million
Q3 2021

Nov 15, 2021

BUY
$80.98 - $109.47 $8.88 Million - $12 Million
109,714 Added 2.57%
4,371,828 $449 Million
Q2 2021

Aug 16, 2021

BUY
$82.78 - $101.0 $17.6 Million - $21.5 Million
212,840 Added 5.26%
4,262,114 $375 Million
Q1 2021

May 17, 2021

BUY
$90.71 - $108.28 $32.8 Million - $39.1 Million
361,508 Added 9.8%
4,049,274 $394 Million
Q4 2020

Feb 16, 2021

BUY
$92.08 - $124.48 $340 Million - $459 Million
3,687,766 New
3,687,766 $414 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.38B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.